Before propensity matching, mothers of tetracycline-exposed infants were more often in the youngest and oldest age strata and ...

In 2017, the CONSORT-CHM Formulas 2017 extension was introduced to enhance the reporting transparency of randomized ...

Net Loss: Net loss attributable to common stockholders for the third quarter of 2024 was $ (3.1) million, or $ (1.92) per ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

AC Immune SA has reported encouraging interim results from its phase 2 VacSYn clinical trial of ACI-7104.056, an ...

Baricitinib significantly reduced SALT scores at 24 weeks, demonstrating superior efficacy over placebo in clinical trials.

The Government wants to introduce legislation around the use of e-scooters, saying they have been left unregulated for too ...

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon”) (Nasdaq: ELDN) today reported its third quarter 2024 operating and financial results and reviewed recent ...

Encouraging findings with immunotherapy aiming at ART-free virological control A significant step towards functional cure of HIV infectionHONG KONG SAR - Media OutReach ...

The trials focused on women with moderate to severe vasomotor symptoms, evaluating fezolinetant's safety and efficacy.